	US 12,285,439 B2
	Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease
Jorge Simón, Bizkaia (ES); María Luz Martínez Chantar, Bizkaia (ES); and Alfonso Martínez De La Cruz, Bizkaia (ES)
Assigned to ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE, Vizcaya (ES)
Appl. No. 17/297,045
Filed by ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE, Vizcaya (ES)
PCT Filed Nov. 26, 2019, PCT No. PCT/EP2019/082606 § 371(c)(1), (2) Date May 26, 2021, PCT Pub. No. WO2020/109316, PCT Pub. Date Jun. 4, 2020.
Claims priority of application No. 18382853 (EP), filed on Nov. 26, 2018.
Prior Publication US 2022/0026444 A1, Jan. 27, 2022
Int. Cl. A61K 31/713 (2006.01); A61P 1/16 (2006.01); A61P 11/00 (2006.01); A61P 13/12 (2006.01); C12N 15/113 (2010.01)

CPC A61K 31/713 (2013.01) [A61P 1/16 (2018.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); C12N 15/113 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01)]

3 Claims

1. A method of treatment of an acute or a chronic disease in a subject, the method comprising administering a Cyclin and CBS domain divalent metal cation transport A mediator (CNNM4) inhibitor to said subject, wherein the CNNM4 inhibitor is selected from siRNA, RNA interference oligonucleotides, shRNA and dicer substrate 27-mer duplex, and wherein the disease is selected from:

a liver disease selected from liver fibrosis, veno-occlusive liver disease, drug-induced liver injury (DILI), steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma (HCC), primary biliary cirrhosis (PBC), primary sclerosing cholangitis, fatty liver, non-alcoholic fatty liver disease (NAFLD), alcoholic hepatitis, Budd-Chiari syndrome, or hepatitis;

a kidney disease selected from acute kidney injury (AKI), chronic kidney disease, nephritis, nephrosis or renal fibrosis; or

a lung disease selected from pulmonary fibrosis or lung adenocarcinoma.